title: Outcomes and duration of Pneumocystis jiroveci pneumonia therapy in infants with severe combined immunodeficiency.
abstract: This retrospective review of patients with severe combined immunodeficiency and Pneumocystis jiroveci pneumonia (PCP) evaluated the relationship between duration of therapy to treat PCP and overall survival. We found that 80% of patients receiving only 21 days of antibiotics survived to 12 months beyond hematopoietic cell transplant, whereas only 25% of patients who required longer treatment for PCP survived to stem cell engraftment.
authors.affiliation: Division of Infectious Diseases, Seattle Children's Hospital, Seattle, WA 98105, USA. dringridlundgren@gmail.com
authors.forename: Ingrid S
authors.initials: IS
authors.lastname: Lundgren
authors.forename: Janet A
authors.initials: JA
authors.lastname: Englund
authors.forename: Lauri M
authors.initials: LM
authors.lastname: Burroughs
authors.forename: Troy R
authors.initials: TR
authors.lastname: Torgerson
authors.forename: Suzanne
authors.initials: S
authors.lastname: Skoda-Smith
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D008297:Male; D045363:Pneumocystis carinii / Q000187:drug effects*; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D016511:Severe Combined Immunodeficiency / Q000150:complications / Q000401:mortality* / Q000628:therapy; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*
chemical_list: D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination